Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

2.

Strategy and rationale for urine collection protocols employed in the NEPTUNE study.

Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M, Bitzer M.

BMC Nephrol. 2015 Nov 17;16:190. doi: 10.1186/s12882-015-0185-3.

3.

Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease.

Hwang YH, Conklin J, Chan W, Roslin NM, Liu J, He N, Wang K, Sundsbak JL, Heyer CM, Haider M, Paterson AD, Harris PC, Pei Y.

J Am Soc Nephrol. 2016 Jun;27(6):1861-8. doi: 10.1681/ASN.2015060648. Epub 2015 Oct 9.

4.

A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease.

Ali H, Hussain N, Naim M, Zayed M, Al-Mulla F, Kehinde EO, Seaburg LM, Sundsbak JL, Harris PC.

BMC Nephrol. 2015 Mar 1;16:26. doi: 10.1186/s12882-015-0015-7.

5.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, Johnson KL, Madden BJ, Zenka RM, McCormick DJ, Sundsbak JL, Heyer CM, Torres VE, Harris PC, Ward CJ.

J Am Soc Nephrol. 2015 Jul;26(7):1661-70. doi: 10.1681/ASN.2014040354. Epub 2014 Dec 4.

6.

Imaging-based diagnosis of autosomal dominant polycystic kidney disease.

Pei Y, Hwang YH, Conklin J, Sundsbak JL, Heyer CM, Chan W, Wang K, He N, Rattansingh A, Atri M, Harris PC, Haider MA.

J Am Soc Nephrol. 2015 Mar;26(3):746-53. doi: 10.1681/ASN.2014030297. Epub 2014 Jul 29.

7.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators.

J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.

8.

Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations.

Freedman BS, Lam AQ, Sundsbak JL, Iatrino R, Su X, Koon SJ, Wu M, Daheron L, Harris PC, Zhou J, Bonventre JV.

J Am Soc Nephrol. 2013 Oct;24(10):1571-86. doi: 10.1681/ASN.2012111089. Epub 2013 Sep 5.

9.

Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families.

Paul BM, Consugar MB, Ryan Lee M, Sundsbak JL, Heyer CM, Rossetti S, Kubly VJ, Hopp K, Torres VE, Coto E, Clementi M, Bogdanova N, de Almeida E, Bichet DG, Harris PC.

Kidney Int. 2014 Feb;85(2):383-92. doi: 10.1038/ki.2013.227. Epub 2013 Jun 12.

10.

Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing.

Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls CG, Torres VE, Harris PC.

J Am Soc Nephrol. 2012 May;23(5):915-33. doi: 10.1681/ASN.2011101032. Epub 2012 Mar 1.

11.

Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation.

Thatava T, Armstrong AS, De Lamo JG, Edukulla R, Khan YK, Sakuma T, Ohmine S, Sundsbak JL, Harris PC, Kudva YC, Ikeda Y.

Stem Cell Res Ther. 2011 Dec 6;2(6):48. doi: 10.1186/scrt89.

12.

Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation.

Syro LV, Sundsbak JL, Scheithauer BW, Toledo RA, Camargo M, Heyer CM, Sekiya T, Uribe H, Escobar JI, Vasquez M, Rotondo F, Toledo SP, Kovacs K, Horvath E, Babovic-Vuksanovic D, Harris PC.

Pituitary. 2012 Sep;15(3):342-9. doi: 10.1007/s11102-011-0325-0.

13.

Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1274-85. doi: 10.2215/CJN.09731110. Epub 2011 May 5.

14.

B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis.

Hopp K, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, Patel P, Consugar MB, Czarnecki PG, Gliem TJ, Torres VE, Rossetti S, Harris PC.

Hum Mol Genet. 2011 Jul 1;20(13):2524-34. doi: 10.1093/hmg/ddr151. Epub 2011 Apr 14.

15.

Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli.

Eto DS, Jones TA, Sundsbak JL, Mulvey MA.

PLoS Pathog. 2007 Jul;3(7):e100.

16.

Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli.

Eto DS, Sundsbak JL, Mulvey MA.

Cell Microbiol. 2006 Apr;8(4):704-17.

PMID:
16548895

Supplemental Content

Loading ...
Support Center